Company intelligence / Profile preview
Jenthera Therapeutics
Montreal/Saint-Laurent, Quebec, Canadajenthera.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Jenthera’s preclinical data show complete eradication of targeted tumors at low doses in both their CAR-T and KRAS programs. Their technology enables high-frequency homology-directed repair and targeted systemic delivery to solid tumors with strong safety profiles regarding off-target effects and immunogenicity. They are currently seeking Series A investment and partnerships to advance toward the clinic.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- CRISPR-Cas gene editing (direct protein delivery)Ribonucleoprotein complexesProtein-based drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Future Fields – collaboration on sustainable mass production of novel proteins using EntoEngine™ biomanufacturing platform for scalable recombinant therapeutic production.
Beyond the preview
Go deeper on Jenthera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jenthera Therapeutics.